BioCardia’s Morph DNA Deflectable Guide Catheter Cleared by FDA
January 14, 2020—BioCardia, Inc. announced FDA 510(k) clearance for the Morph DNA deflectable guide catheter used to guide the Helix biotherapeutic delivery system during CardiAMP cell therapy delivery in the heart.
According to BioCardia, the Morph DNA is designed to enhance procedural control of therapeutic catheters, such as the Helix system, during delivery of cell therapy. It is intended to provide ease of use through bidirectional deflection, reduced torque build-up or whip, enhanced fluoroscopic visibility, and improved ergonomics.
The company noted that helically arranged pullwires in the device, resembling the double helix of a DNA strand, increase catheter stability, rendering it virtually whipless around curves and within the heart. The device also features a new handle design with an adjustable brake for finer catheter control during procedures.
Gerald Koenig, MD, commented in BioCardia’s press release, “The Morph DNA deflectable guide enables navigation within the cardiac chambers without building up torque. This is hugely beneficial for controlling the delivery of therapeutic catheters, such as Helix. The ergonomic features simplify the handling and can reduce procedural delays.” Dr. Koenig is a cardiologist and Principal Investigator of the CardiAMP Heart Failure Trial at Henry Ford Health System in Detroit, Michigan.
advertisement
Featured Video
Conquer the Calcium.
Deliver the Stent.
Sponsored by Cardiovascular Systems Inc.
Related Articles
Top 5 Articles From October 2019
Massive Thromboembolism, PFO, and Acute Limb Ischemia
By Moderator: Mohamad Alkhouli, MD
Panelists: Yashu Dhamija, MD; Abdul Moiz Hafiz, MD; Ankur Kalra, MD, FACP, FACC, FSCAI; and Anmar Kanaa’N, MD
Meeting the Challenge…
By Azeem Latib, MD
Compensation and Production Trends for Interventionalists
A look at MedAxiom’s annual report reflecting the continued evolution of the field in terms of physician demand and compensation agreements.
By Joel Sauer, MBA
TAVR in Small Anatomy
By Moderator: Matias Sztejfman, MD
Panelists: Guilherme Attizzani, MD; Cristian Baeza, MD; Hemal Gada, MD, MBA; Anthony Main, MD; and Henrique Barbosa Ribeiro, MD, PhD
Radial Access for the Evaluation of Bypass Grafts
By Moderator: Mirvat Alasnag, MD, FACP, FSCAI, FRCP
Panelists: James Nolan, MBChB, FRCP, MD; Sunil Rao, MD; and Binita Shah, MD, MS, FACC, FSCAI
Top 5 from EVToday's Current Issue
What’s New in Y-90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Transradial Access for Hepatic Oncologic Interventions
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Contemporary Management of Pancreatic Cancer
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Top Tips in Interventional Oncology
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
